tiprankstipranks
Fosun Pharma’s Drug Registration Boosts Market Prospects
Company Announcements

Fosun Pharma’s Drug Registration Boosts Market Prospects

Shanghai Fosun Pharmaceutical (Group) Co (HK:2196) has released an update.

Don't Miss Our Christmas Offers:

Shanghai Fosun Pharmaceutical’s subsidiary has successfully had its drug registration application for Venlafaxine Hydrochloride Sustained-Release Tablets accepted by China’s National Medical Products Administration. This new drug, aimed at treating depression and generalized anxiety disorder, marks a significant step in Fosun Pharma’s investment in innovative treatments, with approximately RMB 6.17 million already invested in its development.

For further insights into HK:2196 stock, check out TipRanks’ Stock Analysis page.

Related Articles
TipRanks HongKong Auto-Generated NewsdeskShanghai Fosun Pharmaceutical Advances Henlius Merger Plans
TipRanks HongKong Auto-Generated NewsdeskShanghai Fosun Pharma Moves Hong Kong Office
TipRanks HongKong Auto-Generated NewsdeskShanghai Fosun Pharmaceutical Moves Forward with Henlius Merger
Looking for investment ideas? Subscribe to our Smart Investor newsletter for weekly expert stock picks!
Get real-time notifications on news & analysis, curated for your stock watchlist. Download the TipRanks app today! Get the App